Tara Lozy

Ms. Tara Lozy

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Microbiology Spectrum
Verified
Journal Article
Open access
ETElizabeth Titova
Elizabeth Titova
VKVeronica W. Kan
Veronica W. Kan
TLTara Lozy
Tara Lozy
AIAndrew Ip
Andrew Ip
KSKileen Shier
Kileen Shier
David PerlinDavid Perlin
David Perlin
Cancer patients are at risk for severe coronavirus disease 2019 (COVID-19) outcomes due to impaired immune responses. However, the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is inadequately characterized in this population. We hypothesized that cancer vs non-cancer individuals would mount less robust humoral and/or cellular vaccine-induced immune SARS-CoV-2 responses. Receptor binding domain (RBD) and SARS-CoV-2 spike protein antibody levels and T-cell responses were assessed in immunocompetent individuals with no underlying disorders ( n = 479) and immunocompromised individuals ( n = 115). All 594 individuals were vaccinated and of varying COVID-19 statuses (i.e., not known to have been infected, previously infected, or “Long-COVID”). Among immunocompromised individuals, 59% ( n = 68) had an underlying hematologic malignancy; of those, 46% ( n = 31) of individuals received cancer treatment 1,000 U/mL), and of these, 60% ( n = 281) and 44% ( n = 41), respectively, also had elevated T-cell responses. Composite T-cell responses were higher in individuals previously infected with SARS-CoV-2 or those diagnosed with Long-COVID compared to uninfected individuals. T-cell responses varied between immunocompetent vs carcinoma ( n = 12) cohorts ( P < 0.01) but not in immunocompetent vs hematologic malignancy cohorts. Most SARS-CoV-2 vaccinated individuals mounted robust cellular and/or humoral responses, though higher immunogenicity was observed among the immunocompetent compared to cancer populations. The study suggests B-cell targeted therapies suppress antibody responses, but not T-cell responses, to SARS-CoV-2 vaccination. Thus, vaccination continues to be an effective way to induce humoral and cellular immune responses as a likely key preventive measure against infection and/or subsequent more severe adverse outcomes. IMPORTANCE: The study was prompted by a desire to better assess the immune status of patients among our cancer host cohort, one of the largest in the New York metropolitan region. Hackensack Meridian Health is the largest healthcare system in New Jersey and cared for more than 75,000 coronavirus disease 2019 patients in its hospitals. The John Theurer Cancer Center sees more than 35,000 new cancer patients a year and performs more than 500 hematopoietic stem cell transplants. As a result, the work was undertaken to assess the effectiveness of vaccination in inducing humoral and cellular responses within this demographic.

5 August 2023 in Viruses
Verified
Journal Article
Open access
PDF file
JMJosé R. Mediavilla
José R. Mediavilla
TLTara Lozy
Tara Lozy
ALAnnie Lee
Annie Lee
JKJustine Kim
Justine Kim
VKVeronica W. Kan
Veronica W. Kan
BKBarry N Kreiswirth
Barry N Kreiswirth
New Jersey was among the first states impacted by the COVID-19 pandemic, with one of the highest overall death rates in the nation. Nevertheless, relatively few reports have been published focusing specifically on New Jersey. Here we report on molecular, clinical, and epidemiologic observations, from the largest healthcare network in the state, in a cohort of vaccinated and unvaccinated individuals with laboratory-confirmed SARS-CoV-2 infection. We conducted molecular surveillance of SARS-CoV-2-positive nasopharyngeal swabs collected in nine hospitals from December 2020 through June 2022, using both whole genome sequencing (WGS) and a real-time RT-PCR screening assay targeting spike protein mutations found in variants of concern (VOCs) within our region. De-identified clinical data were obtained retrospectively, including demographics, COVID-19 vaccination status, ICU admission, ventilator support, mortality, and medical history. Statistical analyses were performed to identify associations between SARS-CoV-2 variants, vaccination status, clinical outcomes, and medical risk factors. A total of 5007 SARS-CoV-2-positive nasopharyngeal swabs were successfully screened and/or sequenced. Variant screening identified three predominant VOCs, including Alpha (n = 714), Delta (n = 1877), and Omicron (n = 1802). Omicron isolates were further sub-typed as BA.1 (n = 899), BA.2 (n = 853), or BA.4/BA.5 (n = 50); the remaining 614 isolates were classified as “Other”. Approximately 31.5% (1577/5007) of the samples were associated with vaccine breakthrough infections, which increased in frequency following the emergence of Delta and Omicron. Severe clinical outcomes included ICU admission (336/5007 = 6.7%), ventilator support (236/5007 = 4.7%), and mortality (430/5007 = 8.6%), with increasing age being the most significant contributor to each (p < 0.001). Unvaccinated individuals accounted for 79.7% (268/336) of ICU admissions, 78.3% (185/236) of ventilator cases, and 74.4% (320/430) of deaths. Highly significant (p < 0.001) increases in mortality were observed in individuals with cardiovascular disease, hypertension, cancer, diabetes, and hyperlipidemia, but not with obesity, thyroid disease, or respiratory disease. Significant differences (p < 0.001) in clinical outcomes were also noted between SARS-CoV-2 variants, including Delta, Omicron BA.1, and Omicron BA.2. Vaccination was associated with significantly improved clinical outcomes in our study, despite an increase in breakthrough infections associated with waning immunity, greater antigenic variability, or both. Underlying comorbidities contributed significantly to mortality in both vaccinated and unvaccinated individuals, with increasing risk based on the total number of comorbidities. Real-time RT-PCR-based screening facilitated timely identification of predominant variants using a minimal number of spike protein mutations, with faster turnaround time and reduced cost compared to WGS. Continued evolution of SARS-CoV-2 variants will likely require ongoing surveillance for new VOCs, with real-time assessment of clinical impact.

15 February 2024 in Arthritis Care & Research
Verified
Journal Article
Closed access
SLSuzanne C. Li
Suzanne C. Li
CRC. Egla Rabinovich
C. Egla Rabinovich
MBMara L. Becker
Mara L. Becker
KTKathryn S. Torok
Kathryn S. Torok
PFPolly J. Ferguson
Polly J. Ferguson
FIfor the CARRA Registry Investigators
for the CARRA Registry Investigators

21 July 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
JMJosé R. Mediavilla
José R. Mediavilla
TLTara Lozy
Tara Lozy
ALAnnie Lee
Annie Lee
JKJustine Kim
Justine Kim
VKVeronica W. Kan
Veronica W. Kan
BKBarry N Kreiswirth
Barry N Kreiswirth
New Jersey was among the first states impacted by the COVID-19 pandemic, with one of the highest overall death rates in the nation. Nevertheless, relatively few reports have been published focusing specifically on New Jersey. Here we report on molecular, clinical, and epidemiologic observations from the largest healthcare network in the state, in a cohort of vaccinated and unvaccinated individuals with laboratory-confirmed SARS-CoV-2 infection. We conducted molecular surveillance of SARS-CoV-2-positive nasopharyngeal swabs collected in nine hospitals from December 2020 through June 2022, using both whole genome sequencing (WGS) and a real-time RT-PCR screening assay targeting spike protein mutations found in variants of concern (VOC) within our region. De-identified clinical data were obtained retrospectively, including demographics, COVID-19 vaccination status, ICU admission, ventilator support, mortality, and medical history. Statistical analyses were performed to identify associations between SARS-CoV-2 variants, vaccination status, clinical outcomes, and medical risk factors. A total of 5,007 SARS-CoV-2-positive nasopharyngeal swabs were successfully screened and/or sequenced. Variant screening identified three predominant VOC, including Alpha (n =714), Delta (n =1,877), and Omicron (n =1,802). Omicron isolates were further sub-typed as BA.1 (n =899), BA.2 (n =853), and BA.4/BA.5 (n =50); the remaining 614 isolates were classified as “Other”. Approximately 31.5% (1,577/5,007) of the samples were associated with vaccine breakthrough infections, which increased in frequency following the emergence of Delta and Omicron. Severe clinical outcomes included ICU admission (336/5007 = 6.7%), ventilator support (236/5007 = 4.7%), and mortality (430/5007 = 8.6%), with increasing age being the most significant contributor to each (p <0.001). Unvaccinated individuals accounted for 79.7% (268/336) of ICU admissions, 78.3% (185/236) of ventilator cases, and 74.4% (320/430) of deaths. Highly significant (p <0.001) increases in mortality were observed in individuals with cardiovascular disease, hypertension, cancer, diabetes, and hyperlipidemia, but not with obesity, thyroid disease, or respiratory disease. Significant differences (p <0.001) in clinical outcomes were also noted between SARS-CoV-2 variants, including Delta, Omicron BA.1, and Omicron BA.2. Vaccination was associated with significantly improved clinical outcomes in our study, despite an increase in breakthrough infections associated with waning immunity, greater antigenic variability, or both. Underlying comorbidities contributed significantly to mortality in both vaccinated and unvaccinated individuals, with increasing risk based on the total number of comorbidities. Real-time RT-PCR-based screening facilitated timely identification of predominant variants using a minimal number of spike protein mutations, with faster turnaround time and reduced cost compared to WGS. Continued evolution of SARS-CoV-2 variants will likely require ongoing surveillance for new VOCs, with real-time assessment of clinical impact.

5 August 2025 in Journal of Perinatology
Verified
Journal Article
Open access
PDF file
MKMarwa A. Khalil
Marwa A. Khalil
SDSamantha D’aversa
Samantha D’aversa
TLTara Lozy
Tara Lozy
NSNicole T. Spillane
Nicole T. Spillane
Objective: To compare the performance of Fenton Growth Chart (FGC) with WHO Growth Chart (WGC) to identify term infants at risk for hypoglycemia. Study design: A retrospective study of infants screened for hypoglycemia due to SGA or LGA status determined by FGC and/or WGC. Results: Nine hundred and seventy infants were included. There was 47.7% agreement between growth charts. A total of 283 (29.2%) newborns developed hypoglycemia. Of those with hypoglycemia, 53.7% were identified by both charts. WGC was more sensitive for all categories of hypoglycemia examined; hypoglycemia (81.3% [CI 76.2–86.7] vs 72.4% [CI 66.8–77.6]), severe hypoglycemia (80.8% [CI 67.5–90.4] vs 71.2% [CI 56.9–82.9]), and hypoglycemia requiring NICU transfer (88.5% [CI 69.9–97.6] vs 65.4% [CI 44.2–82.8). The FGC was more specific for all hypoglycemia categories. Conclusions: There was poor agreement between WGC and FGC for hypoglycemia in term infants. The WGC was more sensitive in detecting hypoglycemia and was non-inferior to the FGC.

31 August 2026 in JMIR Preprints
Verified
Preprint
Open access
IFIlona Fridman
Ilona Fridman
MDMaame Duah
Maame Duah
DVDiya Vemuganti
Diya Vemuganti
CKChristopher R. Koller
Christopher R. Koller
TLTara Lozy
Tara Lozy
JLJennifer Elston Lafata
Jennifer Elston Lafata
BACKGROUND Patients with cancer increasingly seek information outside clinical offices, including information about complementary and alternative medicine (CAM). However, this also exposes them to misleading content. About 20%–77% of patients make decisions based on external information about CAM without consulting their providers. The current absence of such conversations is a missed opportunity for open, positive information exchange and for establishing trusting patient-provider relationships, both of which are fundamental to informed decision-making, treatment engagement, and improved patient outcomes. OBJECTIVE We report the protocol for a study evaluating the feasibility, acceptability, and preliminary efficacy of a multilevel intervention for oncology providers and patients newly diagnosed with breast or prostate cancer. The intervention has two components. The first is a patient-facing question prompt list (CAM-QPL) that helps patients discuss the information they find outside the clinical office, including information about CAM. The second is a provider-facing communication workshop. METHODS Patients newly diagnosed with breast or prostate cancer are randomized 1:1 to receive either the CAM-QPL or standard educational materials before an oncology visit. Providers are invited to participate; those who consent complete a 60-minute communication workshop. Patients are recruited from both providers who completed the workshop and those who did not, enabling a 2 × 2 quasi-experimental design. Patients complete baseline and follow-up surveys. The primary outcome, patient-reported occurrence of a conversation about health information they encounter outside the clinical office during the oncology visit, will be assessed using mixed-effects logistic regression with patients nested within providers. Secondary outcomes include communication quality, patient activation, CAM-related perceptions measured with items informed by Theory of Planned Behavior, quality of life, and acceptability informed by the Theoretical Framework of Acceptability (TFA). Providers report perceptions of the workshop. Provider pre/post outcomes will be analyzed using paired t-tests or nonparametric alternatives, as appropriate. RESULTS We plan to enroll 132 patients and at least 20 providers. Currently, 19 providers have consented to study participation and completed the workshop, with 32 patients having completed the follow-up survey. CONCLUSIONS This protocol describes the randomized evaluation of the feasibility of a theory-grounded, multilevel intervention designed specifically to facilitate patient–provider conversations about the information patients encounter outside the clinical office, including CAM and cancer misinformation. Findings will inform a future randomized controlled study, as well as provide feedback for future intervention refinement. CLINICALTRIAL